JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (2008) 199, 435-444       DOI: 10.1677/JOE-08-0377
© 2008 Society for Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
JOE-08-0377v1
199/3/435    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Mikhaylova, I. V
Right arrow Articles by Voutilainen, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mikhaylova, I. V
Right arrow Articles by Voutilainen, R.

Leukemia inhibitory factor as a regulator of steroidogenesis in human NCI-H295R adrenocortical cells

Irina V Mikhaylova, Tiina Jääskeläinen1, Jarmo Jääskeläinen, Jorma J Palvimo1 and Raimo Voutilainen

Department of Pediatrics, Kuopio University and University Hospital, PO Box 1777, FI-70211 Kuopio, Finland1 Institute of Biomedicine/Medical Biochemistry, University of Kuopio, PO Box 1627, FI-70211 Kuopio, Finland

(Correspondence should be addressed to R Voutilainen; Email: raimo.voutilainen{at}uku.fi)

Leukemia inhibitory factor (LIF) is a multiple function cytokine regulating the hypothalamic–pituitary–adrenal axis at the pituitary level. LIF and its receptor are expressed in the adrenal glands, suggesting their potential regulatory role also at the adrenal level. Our aim was to clarify the effects of LIF on adrenal steroidogenesis using cell culture conditions. NCI-H295R human adrenocortical cells were treated with LIF (0.01–100 ng/ml) for 3–48 h with or without 8-bromo-cAMP (8-Br-cAMP; 1 mM). LIF treatment augmented cortisol, dehydroepiandrosterone (DHEA), DHEA sulfate, androstenedione, and aldosterone production (up to 224, 211, 149, 229, and 170% of control respectively, P<0.05 for all). It increased basal steroidogenic acute regulatory protein (STAR) and 17{alpha}-hydroxylase/17,20-lyase (CYP17A1) mRNAs (up to 142 and 170% of control respectively, P<0.05) and the respective proteins, but decreased 3β-hydroxysteroid dehydrogenase type 2 (HSD3B2) mRNA (down to 72% of control, P<0.05), and protein. LIF also increased 8-Br-cAMP-induced cortisol and DHEA production and STAR mRNA accumulation, while it attenuated 8-Br-cAMP-induced HSD3B2 expression and androstenedione production. It had an additive effect on tumour necrosis factor-induced cortisol production. LIF had no effect on apoptosis, but it increased slightly the number of metabolically active cells (up to 120% of control, P<0.05). These findings indicate that LIF is a potential physiological and/or pathophysiological regulator of steroidogenesis at the adrenal level.







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society for Endocrinology.